Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma?

Publikation: Bidrag til tidsskriftReviewfagfællebedømt

Dokumenter

  • Glucagon

    Forlagets udgivne version, 5,76 MB, PDF-dokument

Glaucoma is a common ocular neurodegenerative disease characterized by the progressive loss of retinal ganglion cells and their axons. It is the most common cause of irreversible blindness. With an increasing number of glaucoma patients and disease progression despite treatment, it is paramount to develop new and effective therapeutics. Emerging new candidates are the receptor agonists of the incretin hormone glucagon-like-peptide-1 (GLP-1), originally used for the treatment of diabetes. GLP-1 receptor (GLP-1R) agonists have shown neuroprotective effects in preclinical and clinical studies on neurodegenerative diseases in both the brain (e.g., Alzheimer’s disease, Parkinson’s disease, stroke and diabetic neuropathy) and the eye (e.g., diabetic retinopathy and AMD). However, there are currently very few studies investigating the protective effects of GLP-1R agonists in the treatment of specifically glaucoma. Based on a literature search on PubMed, the Cochrane Library, and ClinicalTrials.gov, this review aims to summarize current clinical literature on GLP-1 receptor agonists in the treatment of neurodegenerative diseases to elucidate their potential in future anti-glaucomatous treatment strategies.

OriginalsprogEngelsk
Artikelnummer824054
TidsskriftFrontiers in Neuroscience
Vol/bind16
ISSN1662-4548
DOI
StatusUdgivet - 2022

Bibliografisk note

Publisher Copyright:
Copyright © 2022 Mouhammad, Vohra, Horwitz, Thein, Rovelt, Cvenkel, Williams, Azuara-Blanco and Kolko.

Antal downloads er baseret på statistik fra Google Scholar og www.ku.dk


Ingen data tilgængelig

ID: 300333359